Bullisch
$0.57
Szenariopreis
$0.450
-0.034 (-7.61%)Zum Schluss
NewGenIVF Group Limited is a diversified healthcare and technology-driven platform focused on investments across fertility services, consumer wellness, digital assets, and real estate. The Company operates through three business divisions, which include NewGenProperty, which operates real estate development projects in the United Arab Emirates (UAE)'s Ras Al Khaimah Emirate; NewGenDigital, which serves as the Company's digital asset and decentralized finance (DeFi) solutions arm, and NewGenSup, which focuses on health and longevity products and solutions. Its legacy business involves providing in-vitro fertilization (IVF) and assisted reproductive treatment services, such as surrogacy and egg freezing across Asia.
NIVF is not a good buy right now due to its extremely low price of $0.45, a staggering year-to-date change of -99.98%, and a very low RSI of 15.207, indicating oversold conditions. The stock has also seen a 5-day change of -54.06%, suggesting a strong downward trend. The main risk is the company's recent public offering, which has caused further declines in stock price, and the uncertainty surrounding its financial stability, as evidenced by a forward P/E of 0.0015, indicating potential earnings issues.
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

NewGen IVF Group Sets Pricing for Public Offering

NewGenIVF Completes Convertible Note Exchange Agreement

NewGen's Investment in K25.ai Shows Significant Appreciation

NewGen Acquires Additional 3% Stake in K25.ai, Raising Ownership to 13%

NewGenIVF Acquires Additional Stake in K25.ai
NewGenIVF Group Limited is a diversified healthcare and technology-driven platform focused on investments across fertility services, consumer wellness, digital assets, and real estate. The Company operates through three business divisions, which include NewGenProperty, which operates real estate development projects in the United Arab Emirates (UAE)'s Ras Al Khaimah Emirate; NewGenDigital, which serves as the Company's digital asset and decentralized finance (DeFi) solutions arm, and NewGenSup, which focuses on health and longevity products and solutions. Its legacy business involves providing in-vitro fertilization (IVF) and assisted reproductive treatment services, such as surrogacy and egg freezing across Asia. It operates in the Healthcare sector.
NIVF is not a good buy right now due to its extremely low price of $0.45, a staggering year-to-date change of -99.98%, and a very low RSI of 15.207, indicating oversold conditions. The stock has also seen a 5-day change of -54.06%, suggesting a strong downward trend. The main risk is the company's recent public offering, which has caused further declines in stock price, and the uncertainty surrounding its financial stability, as evidenced by a forward P/E of 0.0015, indicating potential earnings issues.
Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.